Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mesothelin Positive Clear all
Completed Phase 1 Interventional

CART-meso in Mesothelin Expressing Cancers

NCT02159716
View directory record Official record
Conditions
Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer, Malignant Epithelial Pleural Mesothelioma
Interventions
CART-meso
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jun 10, 2026, 1:38 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

NCT03816358
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection, Gemcitabine Hydrochloride, Ipilimumab, Nivolumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 10, 2026, 1:38 AM EDT
Recruiting No phase listed Observational

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

NCT01950572
View directory record Official record
Conditions
Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma, Biliary Tract Neoplasms, Mesothelin Expressing Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

NCT02824042
View directory record Official record
Conditions
Medical Oncology
Interventions
Anetumab ravtansine (BAY94-9343), Itraconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Santa Monica, California • Detroit, Michigan • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jun 10, 2026, 1:38 AM EDT
Completed Phase 1 Interventional Results available

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

NCT04034238
View directory record Official record
Conditions
Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
Interventions
LMB-100, Tofacitinib, Mesothelin Expression
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jun 10, 2026, 1:38 AM EDT
Recruiting Phase 1 Interventional

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

NCT06623396
View directory record Official record
Conditions
Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas, Esophagogastric Adenocarcinoma, Peritoneal Carcinomatosis, Breast Neoplasms, Diabetes Mellitus
Interventions
M28z1XXPD1DNR CAR
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 10, 2026, 1:38 AM EDT
Terminated Phase 2 Interventional Results available

Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

NCT02839681
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Anetumab Ravtansine, Blood test
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Jun 10, 2026, 1:38 AM EDT
Recruiting Phase 1 Interventional

CT-95 in Advanced Cancers Associated With Mesothelin Expression

NCT06756035
View directory record Official record
Conditions
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer
Interventions
CT-95
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

NCT02639091
View directory record Official record
Conditions
Medical Oncology
Interventions
BAY 94-9343, Pemetrexed, Cisplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Chicago, Illinois • Bethesda, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Jun 10, 2026, 1:38 AM EDT
Completed Phase 1 Interventional Results available

CAR T Cells in Mesothelin Expressing Cancers

NCT03054298
View directory record Official record
Conditions
Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer, Mesotheliomas Pleural, Mesothelioma Peritoneum
Interventions
huCART-meso cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 10, 2026, 1:38 AM EDT
Terminated Phase 1 Interventional

CAR T Cells in Mesothelin-Expressing Breast Cancer

NCT05623488
View directory record Official record
Conditions
Breast Cancer
Interventions
huCART-meso cells, Mesothelin Expression Testing
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jun 10, 2026, 1:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

NCT02810418
View directory record Official record
Conditions
Neoplasms, Pancreatic Neoplasms
Interventions
LMB-100, Nab-Paclitaxel, Mesothelin Expression
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Jun 10, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

NCT00325494
View directory record Official record
Conditions
Pancreatic Cancer, Mesothelioma, Ovarian Cancer, Non-Small Cell Lung Cancer
Interventions
MORAb-009
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Jun 10, 2026, 1:38 AM EDT
Terminated Phase 2 Interventional Results available

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04027946
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma of Lung
Interventions
LMB-100, pembrolizumab, Mesothelin Expression, TrueSight Oncology 500
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jun 10, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

NCT02751918
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Anetumab ravtansine (BAY94-9343), Pegylated Liposomal Doxorubicin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Aurora, Colorado • New Haven, Connecticut • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Jun 10, 2026, 1:38 AM EDT
Active, not recruiting Phase 1 Interventional

T-Cell Therapy for Advanced Breast Cancer

NCT02792114
View directory record Official record
Conditions
Breast Cancer, Metastatic HER2-negative Breast
Interventions
Cyclophosphamide, Mesothelin-targeted T cells, AP1903
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jun 10, 2026, 1:38 AM EDT
Terminated Phase 1 Interventional

A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors

NCT02317419
View directory record Official record
Conditions
Cancer
Interventions
RO6927005, gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Jun 10, 2026, 1:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

NCT05451849
View directory record Official record
Conditions
Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
Interventions
TC-510, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
TCR2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jun 10, 2026, 1:38 AM EDT
Terminated Phase 1 Interventional

A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

NCT06523803
View directory record Official record
Conditions
Mesothelin-expressing Advanced Cancers
Interventions
ZW171
Drug
Lead sponsor
Zymeworks BC Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jun 10, 2026, 1:38 AM EDT
Withdrawn Phase 1 Interventional

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

NCT05375825
View directory record Official record
Conditions
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant, Mesothelin (Msln)
Interventions
Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
Procedure · Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Jun 10, 2026, 1:38 AM EDT
Recruiting Phase 1 Interventional

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

NCT05568680
View directory record Official record
Conditions
Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
Interventions
SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Biological
Lead sponsor
Verismo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Westwood, Kansas • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 10, 2026, 1:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

NCT03907852
View directory record Official record
Conditions
Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, High Grade Ovarian Serous Adenocarcinoma
Interventions
gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
TCR2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jun 10, 2026, 1:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

NCT03126630
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jun 10, 2026, 1:38 AM EDT
Terminated Phase 1 Interventional Results available

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

NCT03455556
View directory record Official record
Conditions
Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Anetumab Ravtansine, Atezolizumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jun 10, 2026, 1:38 AM EDT